PDCD1 and glioblastoma: Here we present a case of a patient with BRAFV600E and PD-1-positive GBM who received novel preradiation of chemotherapy and immune checkpoint inhibitors, followed by the addition of RAF/MEK-targeted therapy after initial progression.